Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anatoliy Bushnev"'
Autor:
Kiran S. Toti, Nicole Pribut, Michael D’Erasmo, Madhuri Dasari, Savita K. Sharma, Perry W. Bartsch, Samantha L. Burton, Hannah B. Gold, Anatoliy Bushnev, Cynthia A. Derdeyn, Adriaan E. Basson, Dennis C. Liotta, Eric J. Miller
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2023)
Nucleoside- and nucleotide-based therapeutics are indispensable treatment options for patients suffering from malignant and viral diseases. These agents are most commonly administered to patients as prodrugs to maximize bioavailability and efficacy.
Externí odkaz:
https://doaj.org/article/95897a2077a94f00b1666c0194367d18
Autor:
Sarah T. Pruett, Anatoliy Bushnev, Kerri Hagedorn, Madhura Adiga, Christopher A. Haynes, M. Cameron Sullards, Dennis C. Liotta, Alfred H. Merrill, Jr.
Publikováno v:
Journal of Lipid Research, Vol 49, Iss 8, Pp 1621-1639 (2008)
“Sphingosin” was first described by J. L. W. Thudichum in 1884 and structurally characterized as 2S,3R,4E-2-aminooctadec-4-ene-1,3-diol in 1947 by Herb Carter, who also proposed the designation of “lipides derived from sphingosine as sphingolip
Externí odkaz:
https://doaj.org/article/3a4d6d1be7564f24b6416634e47d1a16
Autor:
Alfred H. Merrill, Dennis C. Liotta, Dirck L. Dillehay, M. Cameron Sullards, Sarah T. Pruett, Jeremy C. Allegood, Suzanne G. Mays, Harsha Ramaraju, Qiong Peng, Anatoliy Bushnev, Holly Symolon
Supplementary Methods and Results from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53635582c1aab65452d6dd31168e961c
https://doi.org/10.1158/1535-7163.22502079
https://doi.org/10.1158/1535-7163.22502079
Autor:
Alfred H. Merrill, Dennis C. Liotta, Dirck L. Dillehay, M. Cameron Sullards, Sarah T. Pruett, Jeremy C. Allegood, Suzanne G. Mays, Harsha Ramaraju, Qiong Peng, Anatoliy Bushnev, Holly Symolon
Supplementary Figures 1-6 from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ec397518129adf12f4a11a6f645182a
https://doi.org/10.1158/1535-7163.22502085
https://doi.org/10.1158/1535-7163.22502085
Autor:
Alfred H. Merrill, Dennis C. Liotta, Dirck L. Dillehay, M. Cameron Sullards, Sarah T. Pruett, Jeremy C. Allegood, Suzanne G. Mays, Harsha Ramaraju, Qiong Peng, Anatoliy Bushnev, Holly Symolon
Supplementary Material from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43de3ce1c522b807c7c6aca2d1619f79
https://doi.org/10.1158/1535-7163.22502082.v1
https://doi.org/10.1158/1535-7163.22502082.v1
Autor:
Sarah T, Pruett, Anatoliy, Bushnev, Kerri, Hagedorn, Madhura, Adiga, Christopher A, Haynes, M Cameron, Sullards, Dennis C, Liotta, Alfred H, Merrill
Publikováno v:
Journal of Lipid Research
"Sphingosin" was first described by J. L. W. Thudichum in 1884 and structurally characterized as 2S,3R,4E-2-aminooctadec-4-ene-1,3-diol in 1947 by Herb Carter, who also proposed the designation of "lipides derived from sphingosine as sphingolipides."
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b69f517c2a7e73e2f78c94f885668bb2
https://pubmed.ncbi.nlm.nih.gov/18499644
https://pubmed.ncbi.nlm.nih.gov/18499644